1. Market Research
  2. > XenoPort, Inc. – Product Pipeline Review – 2013

XenoPort, Inc. – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 66 pages

XenoPort, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “XenoPort, Inc. - Product Pipeline Review - 2013” provides data on the XenoPort, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, XenoPort, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from XenoPort, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- XenoPort, Inc. - Brief XenoPort, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of XenoPort, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of XenoPort, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the XenoPort, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate XenoPort, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of XenoPort, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the XenoPort, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with XenoPort, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of XenoPort, Inc. and identify potential opportunities in those areas.

Table Of Contents

XenoPort, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
XenoPort, Inc. Snapshot 6
XenoPort, Inc. Overview 6
Key Information 6
Key Facts 6
XenoPort, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
XenoPort, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
XenoPort, Inc. - Pipeline Products Glance 11
XenoPort, Inc. - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
XenoPort, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
XenoPort, Inc. - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
XenoPort, Inc. - Drug Profiles 15
Acamprosate Prodrug 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
arbaclofen placarbil 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
XP-21279 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
XP-21510 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
XP-23687 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
XP-23829 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
XenoPort, Inc. - Pipeline Products by Route of Administration 23
XenoPort, Inc. - Pipeline Products By Mechanism of Action 24
XenoPort, Inc. - Recent Pipeline Updates 25
XenoPort, Inc. - Dormant Projects 30
XenoPort, Inc. - Discontinued Pipeline Products 31
Discontinued Pipeline Product Profiles 31
arbaclofen placarbil 31
XP-20925 31
XenoPort, Inc. - Company Statement 32
XenoPort, Inc. - Locations And Subsidiaries 35
Head Office 35
XenoPort, Inc., Recent Developments 36
XenoPort, Inc.- Press Release 36
Apr 12, 2013: XenoPort Provides Update On Introduction Of Horizant 36
Mar 18, 2013: XenoPort To Present Data From Preclinical And Phase I Studies Of XP23829 At AAN Annual Meeting 2013 36
Mar 18, 2013: XenoPort To Present Data On Arbaclofen Placarbil At AAN Annual Meeting 2013 37
Mar 18, 2013: XenoPort To Present Data On Levodopa Prodrug XP21279 At 2013 AAN Annual Meeting 37
Nov 23, 2010: XenoPort Awarded Grant For Acamprosate Prodrug From The Michael J. Fox Foundation 37
Nov 05, 2010: GlaxoSmithKline And XenoPort Respond To FDA On Horizant For Restless Legs Syndrome 38
Oct 13, 2010: XenoPort To Present Preclinical Data Of XP23829 At ECTRIMS 39
Sep 28, 2010: XenoPort Announces Presentation Of New Data For XP21279 At World Parkinson Congress 39
Sep 13, 2010: XenoPort Announces Plans For Phase III Development Of Arbaclofen Placarbil For Spasticity 40
Jul 23, 2010: Xenoport Announces Presentation Of Preclinical Data For Acamprosate Prodrug At Fragile X Syndrome Conference 41
Jul 23, 2010: XenoPort To Present Preclinical Data Of Acamprosate Prodrug At Fragile X Syndrome Conference 41
Jul 07, 2010: GSK And XenoPort Announce Top-Line Phase IIb Results For GSK1838262/XP13512 As Prophylactic Treatment For Migraine Headache 42
Jun 07, 2010: XenoPort Announces Presentations Of Data For Arbaclofen Placarbil At The Associated Professional Sleep Society Meeting 43
May 03, 2010: XenoPort Announces Presentations Of New Data For Arbaclofen Placarbil At Digestive Disease Week Meeting 43
May 03, 2010: XenoPort Announces Presentations Of New Data For Arbaclofen Placarbil At Digestive Disease Week Meeting 44
Apr 15, 2010: EPO Rules European Patent For XP13512 Is Valid 44
Apr 15, 2010: EPO Rules European Patent For XP13512 Is Valid 44
Apr 12, 2010: XenoPort Announces Presentation Of New Data For Arbaclofen Placarbil At American Academy Of Neurology Meeting 45
Apr 12, 2010: XenoPort Announces Presentations Of New Data For XP13512 At American Academy Of Neurology Meeting 45
Feb 17, 2010: GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant(GSK1838262/XP13512) for RLS 46
Feb 09, 2010: XenoPort Announces Extension Of Horizant Date 46
Feb 09, 2010: XenoPort Announces Extension Of The Horizant PDUFA Date To February 11, 2010 46
Feb 04, 2010: XenoPort Announces Horizant as Brand Name for XP13512 47
Feb 04, 2010: XenoPort Announces Horizant As Brand Name For XP13512 47
Financial Deals Landscape 48
XenoPort, Inc., Deals Summary 48
XenoPort, Inc., Pharmaceuticals and Healthcare, Deal Details 49
Partnerships 49
XenoPort Amends Its Agreement With GlaxoSmithKline For Horizant 49
XenoPort Enters Into Co-Promotion Agreement With GlaxoSmithKline For Solzira 51
GlaxoSmithKline Enters Into An Agreement With XenoPort 53
Licensing Agreements 55
XenoPort Enters Into Licensing Agreement With Xanodyne 55
Equity Offering 57
XenoPort Completes Public Offering Of Common Stock For $46 Million 57
XenoPort Prices An Underwritten Public Offering Of $31 Million 59
XenoPort Completes Public Offering Of $55 Million 61
Xenoport Completes Private Placement Of $40 Million 63
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 66
Disclaimer 66



List of Tables

XenoPort, Inc., Key Information 6
XenoPort, Inc., Key Facts 6
XenoPort, Inc. - Pipeline by Indication, 2013 8
XenoPort, Inc. - Pipeline by Stage of Development, 2013 9
XenoPort, Inc. - Monotherapy Products in Pipeline, 2013 10
XenoPort, Inc. - Phase III, 2013 11
XenoPort, Inc. - Phase II, 2013 12
XenoPort, Inc. - Phase I, 2013 13
XenoPort, Inc. - Pre-Clinical, 2013 14
XenoPort, Inc. - Pipeline By Route of Administration, 2013 23
XenoPort, Inc. - Pipeline Products By Mechanism of Action, 2013 24
XenoPort, Inc. - Recent Pipeline Updates, 2013 25
XenoPort, Inc. - Dormant Developmental Projects,2013 30
XenoPort, Inc. - Discontinued Pipeline Products, 2013 31
XenoPort, Inc., Deals Summary 48
XenoPort Amends Its Agreement With GlaxoSmithKline For Horizant 49
XenoPort Enters Into Co-Promotion Agreement With GlaxoSmithKline For Solzira 51
GlaxoSmithKline Enters Into An Agreement With XenoPort 53
XenoPort Enters Into Licensing Agreement With Xanodyne 55
XenoPort Completes Public Offering Of Common Stock For $46 Million 57
XenoPort Prices An Underwritten Public Offering Of $31 Million 59
XenoPort Completes Public Offering Of $55 Million 61
Xenoport Completes Private Placement Of $40 Million 63



List of Figures

XenoPort, Inc. - Pipeline by Indication, 2013 8
XenoPort, Inc. - Pipeline by Stage of Development, 2013 9
XenoPort, Inc. - Monotherapy Products in Pipeline, 2013 10
XenoPort, Inc. - Pipeline Products By Mechanism of Action, 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.